Treatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis

Figures & data

Figure 1 Studies eligible for inclusion in the meta-analysis.

Abbreviation: RCTs, randomized controlled trials.

Table 1 Baseline characteristics of nine included trials

Study	Treatment line	Total (N)	Treatment arms	Number for analysis	Median age (years)	Median PFS	Median OS	Jadad score
Fuchs et al^Citation23 (2014)	Second-line	335	Ramucirumab 8 mg/kg Placebo	236 115	60 60	NR NR	5.2 3.8	5
Wilke et al^Citation20 (2014)	First-line	655	Ramucirumab 8 mg/kg + PTX Placebo + PTX	327 329	61 61	4.4 2.9	9.6 7.4	5
Shen et al^Citation21 (2015)	Second-line	202	Bevacizumab 2.5 mg/kg/wk + capecitabine + DDP Placebo + capecitabine + DDP	100 102	54.2 55.5	6 6.3	11.4 10.5	5
Satoh et al^Citation22 (2014)	Second-line	261	Lapatinib 1,500 mg qd + PTX PTX	132 129	61 62	5.4 4.4	11 8.9	3
Waddell et al^Citation24 (2013)	First-line	553	Panitumumab + EOC EOC	278 275	63 62	7.4 6	11.3 8.8	3
Ohtsu et al^Citation25(2013)	Second-line	656	Everolimus 10 mg/d Placebo	439 217	62 62	1.7 1.4	5.4 4.3	5
Lordick et al^Citation26 (2013)	First-line	904	Cetuximab + capecitabine + DDP Capecitabine + DDP	455 449	60 59	4.4 5.6	9.4 10.7	3
Ohtsu et al^Citation27 (2011)	First-line	774	Bevacizumab 2.5 mg/kg/wk + capecitabine + DDP Placebo + capecitabine + DDP	386 381	58 59	6.7 5.3	12.1 10.1	5
Bang et al^Citation28 (2010)	First-line	594	Trastuzumab + chemotherapy Chemotherapy	294 290	59.4 58.5	6.7 5.5	13.8 11.1	3

Abbreviations: PTX, paclitaxel; DDP, cisplatin; EOC, epirubicin plus oxaliplatin plus capecitabine; PFS, progression-free survival; OS, overall survival; NR, not reported.

Figure 2 RR of severe AEs (95% CI) associated with therapies with or without MTAs.

Abbreviations: RR, relative risk; AEs, adverse events; MTAs, molecular targeted agents; CI, confidence interval; Ev, events; trt, treatments; ctrl, control.

Figure 3 RR of FAEs (95% CI) associated with therapies with or without MTAs.

Abbreviations: RR, relative risk; FAEs, fatal adverse events; MTAs, molecular targeted agents; CI, confidence interval; Ev, events; trt, treatments; ctrl, control.

Table 2 FAEs by specific type

	Events on MTAs groups	Events on control arms
Unspecified	21	23
Specified
Infections	8	7
Hemorrhage	4	2
Arterial thromboembolic events	4	2
Pulmonary embolism	2	2
GI perforation	2	1
Sudden death	3	2
Diarrhea	1	1
Malabsorption	2	–
Renal failure	–	2
Cardiac failure	1	1
Cardiac arrest	1	–
Subileus	–	1
Multiorgan failure	–	1
Dehydration	–	1
Overall	49	46

Abbreviations: FAEs, fatal adverse events; GI, gastrointestinal; MTAs, molecular targeted agents.

FuchsCSTomasekJYongCJRamucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, Phase III trialLancet20143839911313924094768

 PubMed Web of Science ®Google Scholar

WilkeHMuroKVan CutsemERamucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised Phase III trialLancet Oncol201415111224123525240821

 PubMed Web of Science ®Google Scholar

ShenLLiJXuJBevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, Phase III study (AVATAR study)Gastric cancer201518116817624557418

 PubMed Web of Science ®Google Scholar

SatohTXuRHChungHCLapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN – a randomized, Phase III studyJ Clin Oncol201432192039204924868024

 PubMed Web of Science ®Google Scholar

WaddellTChauICunninghamDEpirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label Phase III trialLancet Oncol201314648148923594787

 PubMed Web of Science ®Google Scholar

OhtsuAAjaniJABaiYXEverolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, Phase III GRANITE-1 studyJ Clin Oncol201331313935394324043745

 PubMed Web of Science ®Google Scholar

LordickFKangYKChungHCCapecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label Phase III trialLancet Oncol201314649049923594786

 PubMed Web of Science ®Google Scholar

OhtsuAShahMAVan CutsemEBevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled Phase III studyJ Clin Oncol201129303968397621844504

 PubMed Web of Science ®Google Scholar

BangYJVan CutsemEFeyereislovaATrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase III, open-label, randomised controlled trialLancet2010376974268769720728210

 PubMed Web of Science ®Google Scholar